Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00374244 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Pimozide Augmentation for Clozapine Partial Response
A Phase 2 study of Schizophrenia, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT00374244 is a Phase 2 study of Schizophrenia that has completed, run by Yale University. The registered enrollment target is 28 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00374244, a Phase 2 study of Schizophrenia, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a 12 week outpatient study for patients with schizophrenia who are on Clozapine, but continue to experience symptoms. The purpose of this project is to find out if small doses of pimozide (an antipsychotic medication, taken by mouth) will be helpful in reducing symptoms (such as hearing voices, having trouble in organizing your thoughts, lack of interest in life events and social activities), compared to placebo (an inactive substance, "sugar pill"), when added to clozapine in patients with schizophrenia. The participant will be asked to come in once a week to meet with the research staff and study doctor. The participant will continue to see your regular clinician during this study for all normal appointments. The participant will remain on your current medications throughout the study. During the study you will be randomly selected to be put on a small dose of Pimozide or placebo.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Pimozide
Study Locations (2)
Connecticut
- Connecticut Mental Health Center - New Haven
- VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2004-01 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00374244
The ClinicalTrials.gov registry entry for NCT00374244 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (87% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00374244 reports 2 study locations spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00374244 about?
NCT00374244 is a clinical study titled "Efficacy of Pimozide Augmentation for Clozapine Partial Response". This is a 12 week outpatient study for patients with schizophrenia who are on Clozapine, but continue to experience symptoms. The purpose of this project is to find out if small doses of pimozide (an antipsychotic medication, taken by mouth) will be helpful in reducing symptoms (such as hearing voic...
What is the current status of trial NCT00374244?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2004-01. Estimated completion is 2011-06.
What conditions does trial NCT00374244 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00374244?
The interventions under investigation include: placebo (DRUG), Pimozide (DRUG).
Who is sponsoring clinical trial NCT00374244?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00374244 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.